argenx SE beats top-line and bottom-line estimates; reaffirms FY25 outlook

* argenx SE press release [https://seekingalpha.com/pr/20285593-argenx-reports-third-quarter-2025-financial-results-and-provides-business-update] (ARGX [https://seekingalpha.com/symbol/ARGX]): Q3 GAAP EPS of $5.18 beats by $0.83.
* Revenue of $1.15B (+95.3% Y/Y) beats by $90M.
* Product net sales of VYVGART for the three and nine months ended September 30, 2025, were $1.1 billion and $2.9 billion, respectively, compared to $0.6 billion and $1.4 billion, respectively, for the same periods in 2024.
*
FINANCIAL GUIDANCE: The financial guidance on the combined research and development and selling, general and administrative remains unchanged at approximately $2.5 billion.

MORE ON ARGENX SE

* Argenx SE (ARGX) Discusses On R&D Spotlight | Pioneering MuSK Biology With ARGX-119 Conference (Transcript) [https://seekingalpha.com/article/4823438-argenx-se-argx-discusses-on-r-and-d-spotlight-pioneering-musk-biology-with-argx-119-conference-transcript]
* argenx SE (ARGX) Special Call - Slideshow [https://seekingalpha.com/article/4823450-argenx-se-argx-special-call-slideshow]
* argenx: Bullish On This R&D Focused Biotech Stock [https://seekingalpha.com/article/4822408-argenx-bullish-on-this-r-and-d-focused-biotech-stock]
* argenx SE Q3 2025 Earnings Preview [https://seekingalpha.com/news/4510306-argenx-se-q3-2025-earnings-preview]
* Baron Health Care Fund buys ABBV, UNH, ROIV; exits WAT and COO [https://seekingalpha.com/news/4509225-baron-health-care-fund-buys-abbv-unh-roiv-exits-wat-and-coo]